{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:16:39Z","timestamp":1783433799433,"version":"3.54.6"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC19_0124"],"award-info":[{"award-number":["AC19_0124"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01684"],"award-info":[{"award-number":["PI19\/01684"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare response (reduction in headache frequency and differences in patient\u2010reported outcomes) between Erenumab and OnabotulinumtoxinA from two phase\u2010IV trials after 6\u2009months of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials\/Methods<\/jats:title>\n                    <jats:p>\n                      A prospective cohort study included two parallel cohorts of chronic migraine patients treated with either Erenumab 140\u2009mg\/month or OnabotulinumtoxinA 195\u2009U every 3\u2009months. Participants had no additional preventive therapies or comorbid psychiatric or chronic pain conditions. Baseline data collected included demographics, monthly headache (MHD) and migraine days (MMD), impact scales (MIDAS, HIT\u20106, MSQ), and anxiety\/depression scores (BAI, BDI\u2010II). Assessments were repeated at 6\u2009months. Baseline characteristics were balanced. Efficacy analysis (measured by reduction in MHD\/MMD and impact scales) was conducted using paired\n                      <jats:italic>t<\/jats:italic>\n                      \u2010test, and linear regression models compared treatment\u2010related changes between groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 114 patients were analyzed (57 per group), with no significant baseline differences. Both treatments produced significant reductions in headache frequency at 6\u2009months (Erenumab: \u22127.93 MHD and \u22125.36\u2009MMD,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; OnabotA: \u22126.00 MHD and \u22124.31\u2009MMD,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), without statistically significant differences between therapies. Significant improvements were observed in HIT\u20106 and MSQ scores in both cohorts (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The Erenumab group showed significant reductions in MIDAS, BDI, and BAI scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Differences between treatments were significant for MIDAS improvements at three and 6\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Erenumab and OnabotulinumtoxinA are effective preventive treatments for chronic migraine. No significant differences were found in the magnitude of headache reduction at 3 or 6\u2009months when comparing both treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ene.70654","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:52:18Z","timestamp":1782395538000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erenumab and\n                    <scp>OnabotulinumtoxinA<\/scp>\n                    in Chronic Migraine: A Comparative Analysis"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0514-6001","authenticated-orcid":false,"given":"Mar\u00eda","family":"Garc\u00e9s\u2010Pellejero","sequence":"first","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall D'hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-4134","authenticated-orcid":false,"given":"Marta","family":"Torres\u2010Ferr\u00fas","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall D'hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7064-904X","authenticated-orcid":false,"given":"Rut","family":"Mas\u2010de\u2010les\u2010Valls","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-0267","authenticated-orcid":false,"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall D'hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5296-9401","authenticated-orcid":false,"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall D'hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5286-7605","authenticated-orcid":false,"given":"Eulalia","family":"Gin\u00e9\u2010Cipr\u00e9s","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall D'hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo\u2010Rosich","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department Hospital Universitari Vall D'hebron  Barcelona Spain"},{"name":"Headache and Neurological Pain Research Group, Vall D'hebron Research Institute, Departament de Medicina Universitat Aut\u00f2noma de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01941.x"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.06.001"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14431"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001418"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2017.09.008"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.33588\/rn.7401.2021182"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13653"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211053571"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01766.x"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-022-00452-3"},{"key":"e_1_2_13_12_1","volume-title":"Summary of Product Characteristics: Aimovig, Emgality, Ajovy, Vyepti","author":"European Medicines Agency","year":"2024"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20102982.2010.01993"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010020\u201001157\u20108"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13765"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221123058"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(17)30083\u20102"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ene.70654","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.70654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:39:34Z","timestamp":1783431574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.70654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ene.70654"],"URL":"https:\/\/doi.org\/10.1111\/ene.70654","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70654"}}